A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Nemolizumab in Patients with Acquired Reactive Perforating Collagenosis
Phase 2
- Conditions
- Acquired Reactive Perforating Collagenosis
- Registration Number
- JPRN-jRCT2021230034
- Lead Sponsor
- Tomoyuki Nishiura
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Patients aged 18 years or older who have been diagnosed with acquired reactive perforating collagen fibrosis according to the diagnostic criteria of the Clinical Practice Guide for Perforated Dermatoses (2020)
Exclusion Criteria
Patients with immune deficiency
Patients with body weight less than 30.0kg
Patients with Hepatitis B virus or hepatitis C virus infection
Patients with Evidence of tuberculosis (TB) infection
Pregnant or lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method